PURPOSE: Biliary tract cancers (BTCs), which include intrahepatic cholangiocarcinoma (ICC), extrahepatic cholangiocarcinoma (EHC), and gallbladder cancer (GBC), have limited treatment options. We sought to comprehensively examine the clinical and molecular characteristics of BTCs with amplification or mutation of ERBB2. METHODS: Demographic, outcome, and treatment response data were collected for patients with ERBB2-altered BTC identified by next-generation sequencing with Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets from 2014 to 2018. RESULTS: A total of 517 patients with BTC underwent next-generation sequencing (ICC, n = 313; EHC, n = 93; GBC, n = 111). Twenty-eight patients (5.4%) had ERBB2 alterations, including 2.7% with ERBB2 gene amplification, 2.3% with ERBB2 mutation, and 0.4% with concurrent amplification and mutation. The prevalence of ERBB2 gene alterations was significantly higher in GBC (12.6%) than in ICC (2.2%) and EHC (7.5%; P < .001). In ERBB2-amplified tumors, the median fold change was 6.4 (range, 2.1 to 19.7), while in ERBB2-mutant tumors, the most frequent mutated domain was the extracellular domain (32%), with all mutations in this region involving the S310 codon. Frequent co-altered genes in this cohort were TP53 (54%), PIK3CA (21%), and CDKN2A (18%); KRAS amplification/mutation was found in 7% of patients. One patient with ERBB2-amplified EHC who enrolled in a basket trial (ClinicalTrials.gov identifier: NCT02675829) had a partial response to the human epidermal growth factor receptor 2-targeted antibody-drug conjugate ado-trastuzumab emtansine. CONCLUSION: ERBB2 alterations are present in 5.4% of BTCs. When present, the degree of ERBB2 gene amplification is often high, and S310 codon mutations are the most common hotspot. These features, along with the presented case, support further development of human epidermal growth factor receptor 2-targeted therapy in ERBB2-mutant and/or -amplified BTC.
PURPOSE:Biliary tract cancers (BTCs), which include intrahepatic cholangiocarcinoma (ICC), extrahepatic cholangiocarcinoma (EHC), and gallbladder cancer (GBC), have limited treatment options. We sought to comprehensively examine the clinical and molecular characteristics of BTCs with amplification or mutation of ERBB2. METHODS: Demographic, outcome, and treatment response data were collected for patients with ERBB2-altered BTC identified by next-generation sequencing with Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets from 2014 to 2018. RESULTS: A total of 517 patients with BTC underwent next-generation sequencing (ICC, n = 313; EHC, n = 93; GBC, n = 111). Twenty-eight patients (5.4%) had ERBB2 alterations, including 2.7% with ERBB2 gene amplification, 2.3% with ERBB2 mutation, and 0.4% with concurrent amplification and mutation. The prevalence of ERBB2 gene alterations was significantly higher in GBC (12.6%) than in ICC (2.2%) and EHC (7.5%; P < .001). In ERBB2-amplified tumors, the median fold change was 6.4 (range, 2.1 to 19.7), while in ERBB2-mutant tumors, the most frequent mutated domain was the extracellular domain (32%), with all mutations in this region involving the S310 codon. Frequent co-altered genes in this cohort were TP53 (54%), PIK3CA (21%), and CDKN2A (18%); KRAS amplification/mutation was found in 7% of patients. One patient with ERBB2-amplified EHC who enrolled in a basket trial (ClinicalTrials.gov identifier: NCT02675829) had a partial response to the humanepidermal growth factor receptor 2-targeted antibody-drug conjugate ado-trastuzumab emtansine. CONCLUSION:ERBB2 alterations are present in 5.4% of BTCs. When present, the degree of ERBB2 gene amplification is often high, and S310 codon mutations are the most common hotspot. These features, along with the presented case, support further development of humanepidermal growth factor receptor 2-targeted therapy in ERBB2-mutant and/or -amplified BTC.
Authors: David M Hyman; Sarina A Piha-Paul; Helen Won; Jordi Rodon; Cristina Saura; Geoffrey I Shapiro; Dejan Juric; David I Quinn; Victor Moreno; Bernard Doger; Ingrid A Mayer; Valentina Boni; Emiliano Calvo; Sherene Loi; Albert C Lockhart; Joseph P Erinjeri; Maurizio Scaltriti; Gary A Ulaner; Juber Patel; Jiabin Tang; Hannah Beer; S Duygu Selcuklu; Aphrothiti J Hanrahan; Nancy Bouvier; Myra Melcer; Rajmohan Murali; Alison M Schram; Lillian M Smyth; Komal Jhaveri; Bob T Li; Alexander Drilon; James J Harding; Gopa Iyer; Barry S Taylor; Michael F Berger; Richard E Cutler; Feng Xu; Anna Butturini; Lisa D Eli; Grace Mann; Cynthia Farrell; Alshad S Lalani; Richard P Bryce; Carlos L Arteaga; Funda Meric-Bernstam; José Baselga; David B Solit Journal: Nature Date: 2019-02 Impact factor: 49.962
Authors: Maeve A Lowery; Ryan Ptashkin; Emmet Jordan; Michael F Berger; Ahmet Zehir; Marinela Capanu; Nancy E Kemeny; Eileen M O'Reilly; Imane El-Dika; William R Jarnagin; James J Harding; Michael I D'Angelica; Andrea Cercek; Jaclyn F Hechtman; David B Solit; Nikolaus Schultz; David M Hyman; David S Klimstra; Leonard B Saltz; Ghassan K Abou-Alfa Journal: Clin Cancer Res Date: 2018-05-30 Impact factor: 12.531
Authors: John N Primrose; Richard P Fox; Daniel H Palmer; Hassan Z Malik; Raj Prasad; Darius Mirza; Alan Anthony; Pippa Corrie; Stephen Falk; Meg Finch-Jones; Harpreet Wasan; Paul Ross; Lucy Wall; Jonathan Wadsley; Jeff T R Evans; Deborah Stocken; Raaj Praseedom; Yuk Ting Ma; Brian Davidson; John P Neoptolemos; Tim Iveson; James Raftery; Shihua Zhu; David Cunningham; O James Garden; Clive Stubbs; Juan W Valle; John Bridgewater Journal: Lancet Oncol Date: 2019-03-25 Impact factor: 41.316
Authors: D J Slamon; B Leyland-Jones; S Shak; H Fuchs; V Paton; A Bajamonde; T Fleming; W Eiermann; J Wolter; M Pegram; J Baselga; L Norton Journal: N Engl J Med Date: 2001-03-15 Impact factor: 91.245
Authors: Yelena Y Janjigian; Francisco Sanchez-Vega; Philip Jonsson; Walid K Chatila; Jaclyn F Hechtman; Geoffrey Y Ku; Jamie C Riches; Yaelle Tuvy; Ritika Kundra; Nancy Bouvier; Efsevia Vakiani; Jianjiong Gao; Zachary J Heins; Benjamin E Gross; David P Kelsen; Liying Zhang; Vivian E Strong; Mark Schattner; Hans Gerdes; Daniel G Coit; Manjit Bains; Zsofia K Stadler; Valerie W Rusch; David R Jones; Daniela Molena; Jinru Shia; Mark E Robson; Marinela Capanu; Sumit Middha; Ahmet Zehir; David M Hyman; Maurizio Scaltriti; Marc Ladanyi; Neal Rosen; David H Ilson; Michael F Berger; Laura Tang; Barry S Taylor; David B Solit; Nikolaus Schultz Journal: Cancer Discov Date: 2017-11-09 Impact factor: 39.397
Authors: Bob T Li; Ronglai Shen; Darren Buonocore; Zachary T Olah; Ai Ni; Michelle S Ginsberg; Gary A Ulaner; Michael Offin; Daniel Feldman; Todd Hembrough; Fabiola Cecchi; Sarit Schwartz; Nick Pavlakis; Stephen Clarke; Helen H Won; Edyta B Brzostowski; Gregory J Riely; David B Solit; David M Hyman; Alexander Drilon; Charles M Rudin; Michael F Berger; Jose Baselga; Maurizio Scaltriti; Maria E Arcila; Mark G Kris Journal: J Clin Oncol Date: 2018-07-10 Impact factor: 44.544
Authors: Dara S Ross; Ahmet Zehir; Donavan T Cheng; Ryma Benayed; Khedoudja Nafa; Jaclyn F Hechtman; Yelena Y Janjigian; Britta Weigelt; Pedram Razavi; David M Hyman; José Baselga; Michael F Berger; Marc Ladanyi; Maria E Arcila Journal: J Mol Diagn Date: 2016-12-25 Impact factor: 5.568
Authors: Milind Javle; Tanios Bekaii-Saab; Apurva Jain; Ying Wang; Robin Katie Kelley; Kai Wang; Hyunseon C Kang; Daniel Catenacci; Siraj Ali; Sunil Krishnan; Daniel Ahn; Andrea Grace Bocobo; Mingxin Zuo; Ahmed Kaseb; Vincent Miller; Philip J Stephens; Funda Meric-Bernstam; Rachna Shroff; Jeffrey Ross Journal: Cancer Date: 2016-09-13 Impact factor: 6.860
Authors: T Okusaka; K Nakachi; A Fukutomi; N Mizuno; S Ohkawa; A Funakoshi; M Nagino; S Kondo; S Nagaoka; J Funai; M Koshiji; Y Nambu; J Furuse; M Miyazaki; Y Nimura Journal: Br J Cancer Date: 2010-07-13 Impact factor: 7.640
Authors: Salvatore Galdy; Angela Lamarca; Mairéad G McNamara; Richard A Hubner; Chiara A Cella; Nicola Fazio; Juan W Valle Journal: Cancer Metastasis Rev Date: 2017-03 Impact factor: 9.264
Authors: Simon Gray; Angela Lamarca; Julien Edeline; Heinz-Josef Klümpen; Richard A Hubner; Mairéad G McNamara; Juan W Valle Journal: Cancers (Basel) Date: 2022-03-31 Impact factor: 6.639
Authors: Li Wang; Xiaomo Li; Yurong Cheng; Jing Yang; Si Liu; Tonghui Ma; Li Luo; Yanping Hu; Yi Cai; Dong Yan Journal: Front Immunol Date: 2022-01-06 Impact factor: 7.561